JP2014521653A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521653A5
JP2014521653A5 JP2014523015A JP2014523015A JP2014521653A5 JP 2014521653 A5 JP2014521653 A5 JP 2014521653A5 JP 2014523015 A JP2014523015 A JP 2014523015A JP 2014523015 A JP2014523015 A JP 2014523015A JP 2014521653 A5 JP2014521653 A5 JP 2014521653A5
Authority
JP
Japan
Prior art keywords
nitrogen
sulfur
oxygen
ring
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014523015A
Other languages
English (en)
Japanese (ja)
Other versions
JP6006794B2 (ja
JP2014521653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048368 external-priority patent/WO2013019561A1/en
Publication of JP2014521653A publication Critical patent/JP2014521653A/ja
Publication of JP2014521653A5 publication Critical patent/JP2014521653A5/ja
Application granted granted Critical
Publication of JP6006794B2 publication Critical patent/JP6006794B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014523015A 2011-07-29 2012-07-26 核内輸送調節因子およびその使用 Active JP6006794B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161513428P 2011-07-29 2011-07-29
US201161513432P 2011-07-29 2011-07-29
US61/513,428 2011-07-29
US61/513,432 2011-07-29
US201261653588P 2012-05-31 2012-05-31
US61/653,588 2012-05-31
PCT/US2012/048368 WO2013019561A1 (en) 2011-07-29 2012-07-26 Nuclear transport modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016176098A Division JP2016199604A (ja) 2011-07-29 2016-09-09 核内輸送調節因子およびその使用

Publications (3)

Publication Number Publication Date
JP2014521653A JP2014521653A (ja) 2014-08-28
JP2014521653A5 true JP2014521653A5 (enExample) 2015-08-20
JP6006794B2 JP6006794B2 (ja) 2016-10-12

Family

ID=46682903

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014523015A Active JP6006794B2 (ja) 2011-07-29 2012-07-26 核内輸送調節因子およびその使用
JP2016176098A Withdrawn JP2016199604A (ja) 2011-07-29 2016-09-09 核内輸送調節因子およびその使用
JP2018006773A Active JP6752235B2 (ja) 2011-07-29 2018-01-18 核内輸送調節因子およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016176098A Withdrawn JP2016199604A (ja) 2011-07-29 2016-09-09 核内輸送調節因子およびその使用
JP2018006773A Active JP6752235B2 (ja) 2011-07-29 2018-01-18 核内輸送調節因子およびその使用

Country Status (15)

Country Link
US (5) US9428490B2 (enExample)
EP (1) EP2736883B1 (enExample)
JP (3) JP6006794B2 (enExample)
KR (1) KR102022715B1 (enExample)
CN (1) CN103842340B (enExample)
AU (2) AU2016213805A1 (enExample)
BR (1) BR112014001933A2 (enExample)
CA (1) CA2842364A1 (enExample)
CL (2) CL2014000224A1 (enExample)
EA (1) EA201490406A1 (enExample)
MX (1) MX350442B (enExample)
PE (1) PE20141003A1 (enExample)
SG (1) SG10201609097PA (enExample)
UA (1) UA117902C2 (enExample)
WO (1) WO2013019561A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
JP6106605B2 (ja) 2011-01-17 2017-04-05 カリオファーム セラピューティクス,インコーポレイテッド オレフィン含有核輸送調節剤およびその使用
EP2736883B1 (en) * 2011-07-29 2019-09-04 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
JP6005740B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス,インコーポレイテッド ヒドラジド含有核輸送調節因子およびその使用
AU2013259384B2 (en) 2012-05-09 2016-06-02 Biogen Ma Inc. Nuclear transport modulators and uses thereof
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP2968278B8 (en) * 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205389A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
BR112016000779A8 (pt) 2013-07-18 2020-01-07 Novartis Ag inibidores de autotaxina que compreendem núcleo do ciclo de benzilamida de anel heteroaromático, seus usos, composição e combinação farmacêuticas
US9469650B2 (en) 2013-11-08 2016-10-18 Board Of Trustees Of The University Of Arkansas Melampomagnolide B derivatives
US9487536B2 (en) 2013-11-08 2016-11-08 Board Of Trustees Of The University Of Arkansas Melampomagnolide B derivatives
JP6527149B2 (ja) * 2013-11-28 2019-06-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ベータ−サラセミアの処置のための方法及び医薬組成物
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
MX388170B (es) 2014-08-15 2025-03-19 Karyopharm Therapeutics Inc Polimorfos de selinexor
US9981990B2 (en) 2014-12-03 2018-05-29 Bioventures, Llc Melampomagnolide B dimers
CA2971835A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
EP3325474A1 (en) 2015-07-24 2018-05-30 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
ES2930848T3 (es) 2015-09-23 2022-12-22 Xwpharma Ltd Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos
KR20250136942A (ko) 2015-10-06 2025-09-16 프로테오스타시스 테라퓨틱스, 인크. Cftr 조절용 화합물, 조성물, 및 방법
CN105384673B (zh) * 2015-11-09 2017-11-14 南京富润凯德生物医药有限公司 3‑氟代‑氮杂环丁烷衍生物的合成方法
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
JP2019509980A (ja) * 2016-01-29 2019-04-11 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC メランポマグノリドbのトリアゾール誘導体及びその使用方法
MA43775A (fr) 2016-04-07 2021-05-05 Proteostasis Therapeutics Inc Analogues du ivacaftor conentant des atomes de silicium
WO2017212423A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemcical compounds
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3512515A1 (en) 2016-09-16 2019-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
CN115025086A (zh) 2017-03-30 2022-09-09 凯瑞康宁生物工程(武汉)有限公司 双环杂芳基衍生物及其制备与用途
CA3087912C (en) 2018-01-10 2023-03-14 Xw Laboratories Inc. Prodrugs of ketamine, compositions and uses thereof
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN110592141B (zh) * 2018-06-13 2023-07-07 中国科学院上海有机化学研究所 用于调控基因编辑效率的化合物及其应用
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程(武汉)有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
JP2020141256A (ja) 2019-02-28 2020-09-03 ソニーセミコンダクタソリューションズ株式会社 復調回路、復調方法、送信装置
KR20220004142A (ko) 2019-05-01 2022-01-11 카리오팜 쎄라퓨틱스, 인코포레이티드 Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 4-纈胺醯氧基丁酸的合成方法
WO2021257832A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
KR20230011359A (ko) 2020-06-18 2023-01-20 엑스더블유파마 리미티드 수용성 활성 약제 성분의 제어 방출 과립화물
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022143779A1 (zh) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 含烯基类化合物及其应用
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
JP7737544B2 (ja) 2021-08-13 2025-09-10 エックスダブリューファーマ リミテッド ケタミン誘導体の医薬組成物及び経口剤形
WO2024175804A1 (en) * 2023-02-24 2024-08-29 Katholieke Universiteit Leuven Nuclear transport modulators
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) * 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) * 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
JP2941950B2 (ja) * 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の4−アミノメチル−2−置換イミダゾール誘導体および2−アミノメチル−4−置換イミダゾール誘導体;新規な種類のドーパミン リセプタ亜型特異性リガンド
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (en) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
CN1088711C (zh) * 1996-04-04 2002-08-07 盐野义制药株式会社 头孢烯化合物及含该化合物的医药
CN101817784B (zh) 1996-04-25 2012-02-01 日产化学工业株式会社 乙烯衍生物和含有该衍生物的杀有害生物剂
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) * 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) * 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
CA2423868C (en) * 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
AU2002327627B2 (en) * 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
WO2004037248A2 (en) * 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
CA2504511A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
AU2003291403A1 (en) * 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
CA2512886A1 (en) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
BRPI0511504A (pt) * 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
US20100130737A1 (en) * 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
AR057891A1 (es) 2005-11-15 2007-12-26 Otsuka Pharma Co Ltd Compuestos de oxazol y composicion farmaceutica
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
CN101466670B (zh) * 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
DK2014652T3 (da) 2006-04-18 2014-10-13 Nippon Chemiphar Co Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor
KR101130380B1 (ko) 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
AU2007277519B2 (en) * 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2090570B1 (en) * 2006-09-05 2011-11-09 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
EP1942104A1 (en) * 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
JP6106605B2 (ja) 2011-01-17 2017-04-05 カリオファーム セラピューティクス,インコーポレイテッド オレフィン含有核輸送調節剤およびその使用
US9152882B2 (en) * 2011-06-17 2015-10-06 Microsoft Technology Licensing, Llc. Location-aided recognition
EP2736883B1 (en) * 2011-07-29 2019-09-04 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
JP6005740B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス,インコーポレイテッド ヒドラジド含有核輸送調節因子およびその使用
AU2013259384B2 (en) 2012-05-09 2016-06-02 Biogen Ma Inc. Nuclear transport modulators and uses thereof
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205389A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof

Similar Documents

Publication Publication Date Title
JP2014521653A5 (enExample)
JP2016503009A5 (enExample)
JP2017502940A5 (enExample)
JP2016517878A5 (enExample)
JP2019527718A5 (enExample)
JP2015511638A5 (enExample)
JP2016526576A5 (enExample)
JP2017532360A5 (enExample)
RU2015127822A (ru) Ингибиторы энхансера гомолога 2 белка zeste
JP2019505541A5 (enExample)
JP2010509375A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2013512903A5 (enExample)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2016525104A5 (enExample)
JP2013536193A5 (enExample)
JP2013537203A5 (enExample)
JP2009538897A5 (enExample)
JP2011510080A5 (enExample)
JP2009536620A5 (enExample)
JP2016516043A5 (enExample)
JP2017537948A5 (enExample)
JP2008535903A5 (enExample)
JP2017514809A5 (enExample)
JP2017505293A5 (enExample)